Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

AMGEN INC

AMGNCIK 0000318154Biotechnology

Compare:REGN BIIB VRTX GILD MRNA LLY

Compare AMGN

Intrinsic Value

AMGN Intrinsic Valuation

Review the filing-backed discounted cash flow baseline, scenario range, and capital structure context for a fundamentals-first fair value read.

Intrinsic Value

AMGN Intrinsic Valuation

Review the filing-backed discounted cash flow baseline, scenario range, and capital structure context for a fundamentals-first fair value read.

Intrinsic value

Filing-backed DCF baseline

Automated free-cash-flow DCF baseline for AMGEN INC, derived from annual filing data.

Read the DCF guide

DCF fair value

$130.87

Implied equity value $71B

Current price

—

Latest available quote for the primary listing.

Margin of safety

N/A

Live market price unavailable. Refreshing the route will retry the quote.

Fair value range

$98.66 – $172.82

Bear

$98.66

Base

$130.87

Bull

$172.82

Model assumptions

Cash flow base

$8B

Basis

Operating cash flow less capex (firm-value proxy)

Growth

7.6%

Discount

10.5%

Terminal

2.5%

Horizon

Assumption sensitivity

vs base per share

Base case$130.87Baseline

Growth +1 pt$163.11+$32.23

Intrinsic value

Filing-backed DCF baseline

Automated free-cash-flow DCF baseline for AMGEN INC, derived from annual filing data.

Read the DCF guide

DCF fair value

$130.87

Implied equity value $71B

Current price

—

Latest available quote for the primary listing.

Margin of safety

N/A

Live market price unavailable. Refreshing the route will retry the quote.

Fair value range

$98.66 – $172.82

Bear

$98.66

Base

$130.87

Bull

$172.82

Model assumptions

Cash flow base

$8B

Basis

Operating cash flow less capex (firm-value proxy)

Growth

7.6%

Discount

10.5%

Terminal

2.5%

Horizon

Assumption sensitivity

vs base per share

Base case$130.87Baseline

Growth +1 pt$163.11+$32.23

What the market is pricing in

Market expectations cannot be backed out until price, share count, cash-flow base, discount rate, terminal growth, and the EV-to-equity bridge are all available.
Growth anchor: Median of 3Y revenue CAGR, 5Y revenue CAGR, and 5Y free cash flow CAGR. Scenario-derived from +/-2 pts growth and +/-1 pt discount.
Net debt reduces equity value relative to firm value before the per-share target is calculated.

Intrinsic EV-to-equity bridge

Enterprise value

Discounted free cash flows

$116B

Less total debt

− $55B

Plus cash and equivalents

+ $9B

Equity value

After the bridge

$71B

Diluted shares

542,000,000

Fair value / share

$130.87